Products and Resources Catalog

Pacific Behavioral Health Collaborating Council (PBHCC) IC&RC Alcohol and Drug Counselor (ADC) Academy Curriculum Developed by the Pacific Southwest Addiction Technology Transfer Center and UCLA Integrated Substance Abuse Programs The IC&RC Alcohol and Drug Counselor (ADC) Academy curriculum is a weeklong training designed to prepare individuals based in the six U.S.-affiliated Pacific Jurisdictions to successfully pass the IC&RC ADC certification exam. The duration of the ADC Academy is forty hours of content spread across five full days of training. Funding for the development of the ADC Academy was provided by the Pacific Behavioral Health Collaborating Council (PBHCC). The curriculum is broken into five modules/days, which include: • Day 1: Introduction to the IC&RC ADC Performance Domains and Review of Psychoactive Drugs • Day 2: Core Competencies of Addiction Counselors – Knowledge and Skill Acquisition of Screening, Intake, Orientation, Assessment, Treatment Planning, and Counseling • Day 3: Core Competencies of Addiction Counselors – Knowledge and Skill Acquisition of Case Management, Crisis Intervention, Client and Family Education, Referral, Report and Record Keeping, and Consultation • Day 4: Core Competencies of Addiction Counselors – Prevention and Treatment of HIV/AIDS and Sexually Transmitted Infections • Day 5: Course Review and Test-Taking Strategies To view and download the IC&RC ADC Academy Curriculum, please visit: http://uclaisap.org/slides/icrc-adc-academy-curriculum.html Acknowledgements: This training was developed by Dr. Thomas E. Freese, PhD (Director of Training of UCLA ISAP and Director of the Pacific Southwest ATTC), Alex R. Ngiraingas, MEd, CSAC II, ICADC, ICPS, and Dr. Christopher C. C. Rocchio, PhD, LCSW, CSAC, ICADC (Clinical Specialist, UCLA) in August of 2018 under contract number 2018-002 by the University of California Los Angeles, Integrated Substance Abuse Programs (UCLA ISAP) and the Pacific Southwest Addiction Technology Center (PSATTC) for the Pacific Behavioral Health Collaborating Council (PBHCC). Additional resource provided by SAMHSA, grant number UR1TI080211. *All PowerPoint presentations and trainer guides are 508 compliant.

Currently, women’s involvement in correctional and substance use disorders (SUD) treatment systems is rapidly outpacing men. Most of these programs are based upon gender-neutral services, meaning that their programs were designed with men in mind. Specifically, many of these programs address why men use drugs and alcohol and how to reduce recidivism with little emphasis placed on the treatment needs of women. This is especially worrisome for women in correctional or treatment settings with stimulants as their drug of choice. Statistics demonstrate that women make up more than half of the clients treated for methamphetamine and other stimulants in the majority of SUD treatment programs. As such, a recent study indicated that five times the percentage of females than males attributed initial methamphetamine use to a desire to lose weight and more females than males reported using meth to get more energy. Stimulant use by women often leads to high rates of eating pathologies and compensatory behaviors, body dissatisfaction and preoccupation with body shape, binge eating, nutritional deficiencies, and weight gain among women in treatment for SUDs and in correctional settings.    This webinar will address core issues that are unique to female SUD treatment clients in comparison to their male counterparts regarding weight and energy as a driving mechanism to use, triggers for relapse, trends in drug use for women and the complexity of health-related complications and psychosocial needs, prescription medication and over-the-counter drug manipulation. Finally, gender-responsive approaches to augment and enhance existing treatment services will be discussed. This webinar is based on the Healthy Steps to Freedom program.   Presenter: Anne R. Lindsay, Ph.D. is Associate Professor and Extension Specialist at the University of Nevada, Reno. Her research focuses on gender-responsive approaches to women under correctional supervision for SUDs, particularly those related to nutrition, physical activity, eating pathology, body image, weight and other health-related topics.   

In this webinar in February 2020, Dr. Robrina Walker, University of Texas Southwestern Medical Center, described trends in the use of methamphetamine, presented about evidence-based treatments for methamphetamine use disorder, and summarized current research investigating new treatments for methamphetamine use disorder. This event was co-sponsored by the Western States Node of the NIDA Clinical Trials Network. Download slides | Watch recording

Part 1 of the Great Lakes ATTC/NW ATTC 3-part webinar series provides an overview of stimulant (cocaine and methamphetamine) use in the U.S. Presenter Rick Rawson, Ph.D., will discuss: 1. The extent and geography of stimulant use.  2. Clinical syndromes produced by acute and chronic stimulant use; s.trategies for addressing acute intoxication, withdrawal, and stimulant-induced psychosis.  3. Effective behavioral treatments for stimulant use disorders.  4. The status of pharmacotherapy research on treatments for stimulant use disorders.  5. Vulnerable populations, including the problem of stimulant use by individuals in medication treatment for opioid use disorder.

The second installment of Great Lakes/Northwest ATTC webinar series features a panel of providers presenting their experiences with effective treatment strategies and evidence-based practices for working with individuals with stimulant use disorders. Section 1: Treating Individuals with Stimulant and Opioid Use Disorders – Evergreen Treatment Center in Seattle, WA. K. Michelle Peavy, Ph.D., of Evergreen Treatment Services addresses challenges and strategies of working with individuals with comorbid opioid use and stimulant use disorders. Section 2: Implementing Contingency Management: Lessons Learned from VA’s National Implementation Initiative. Dominick DePhilippis, Ph.D., presents on use of contingency management in the VA system. Section 3: Using the MATRIX Model to treat stimulant disorders in a FQHC setting. Regina Fox, LSW, CSAC, will discuss use of the Matrix Model of treatment in a community-based treatment organization. Download the FAQ Sheet 

During this last installment of the webinar series three presenters will discuss change management strategies for successfully implementing these evidence-based practices. Todd Molfenter, Ph.D., provides an overview on how implementation science informs successful uptake of EBPs. Bryan Hartzler, PhD., presents tips for community-based implementation of contingency management. Denna Vandersloot, M.Ed, shares lessons learned from implementation efforts involving the Matrix Model of treatment.

During this last installment of the webinar series three presenters will discuss change management strategies for successfully implementing these evidence-based practices. The first two installments of the series focused on effective treatment strategies and models for addressing stimulant use disorders. During this webinar, three presenters will discuss change management strategies for successfully implementing these evidence-based practices. Todd Molfenter, Ph.D. will provide an overview on how implementation science informs successful uptake of EBPs. Bryan Hartzler, PhD. will present tips for community-based implementation of contingency management. Denna Vandersloot, M.Ed will share lessons learned from implementation efforts involving the Matrix Model of treatment.

This webinar featured a panel of providers presenting their experiences with effective treatment strategies and evidence-based practices for working with individuals with stimulant use disorders. Michelle Peavy, PhD, of Evergreen Treatment Services, addressed challenges and strategies of working with individuals with comorbid opioid use and stimulant use disorders Dominick DePhilippis, PhD, presented on use of contingency management with this population in the VA system Regina Fox, BS, CSAC discussed use of the Matrix Model of treatment in a community-based treatment organization Watch recording This is part 2 of a 3-part series on Stimulant Use Disorders sponsored by the Northwest and Great Lakes ATTCs. Find the complete series here.  Webinar category: Stimulants, Treatment - General

Methamphetamine use is increasing in the wake of the opioid crisis, particularly in the Western United States. This webinar, presented by Sara Glick, PhD, of the University of Washington School of Medicine, describes current trends across our four-state region (WA, OR, ID, AK), including methamphetamine use among people who inject drugs, health consequences like recent HIV outbreaks, non-fatal and fatal overdose, and treatment interest and options. Sara Glick is a Research Assistant Professor at the UW School of Medicine.

Three-part webinar series offered by the Great Lakes ATTC and the Northwest ATTC. Part 1 of the series provides an overview of stimulant (cocaine and methamphetamine) use in the U.S. Presenter Rick Rawson, PhD will discuss: The extent and geography of stimulant use Clinical syndromes produced by acute and chronic stimulant use Strategies for addressing acute intoxication, withdrawal, and stimulant-induced psychosis Effective behavioral treatments for stimulant use disorders The status of pharmacotherapy research on treatments for stimulant use disorders A discussion of vulnerable populations, including the problem of stimulant use by individuals in medication treatment for opioid use disorder   PowerPoint Presentation  

This webinar, presented by Richard Rawson, PhD, of UCLA and University of Vermont, provided an overview of the current knowledge on the problem of stimulant (cocaine and methamphetamine) use in the U.S., including a review of the extent and geography of use, the clinical syndromes provided by acute and chronic use, a review of behavioral treatments with evidence of efficacy for the treatment of stimulant use disorders, and an overview of the current status of pharmacotherapy research on treatments for stimulant use disorders. Download slides | Watch recording This is part 1 of a 3-part series on Stimulant Use Disorders sponsored by the Northwest and Great Lakes ATTCs. Find the complete series here.  Webinar category: Stimulants, Treatment - General

Overview: Methamphetamine is the number 1 drug threat ranked by the Dallas, El Paso, and Houston DEA Field Divisions. Cocaine is ranked the number 2 and number 3 threat by the DEA Field Divisions. Pharmaceuticals, benzodiazepines, hydrocodone, and muscle relaxants remain problematic. Compared to other NDEWS sites, the number of fentanyl items seized and identified is increasing, but the number of cases involving heroin and fentanyl in combination is low, while the number of cases involving fentanyl and other opiates is high. The recent increase in the number of tramadol cases involved with other opiates is also a concern. Heroin in Texas is either black tar heroin or powdered brown heroin (diluted with diphenhydramine or other filler), with some white Mexican/South American heroin seen. Of the top 25 items seized and identified in Texas laboratories reporting to the National Forensic Laboratory Information System (NFLIS), heroin ranks #4, at 5.2% of all items identified, and fentanyl ranks #21 (0.21% of all items identified). Cannabis indicators remain steady, with problems most often seen in the trafficking of decriminalized cannabis products from Colorado through Texas. Synthetic cannabinoid and cathinone poison calls have decreased but recent research by the author looking at treatment admissions and poison center call data has found statistically significant trends over time. The user population has changed from younger males hoping to use a cannabinoid that would not show positive in drug tests to an older population who are more likely to be experiencing homelessness and co-morbid psychological problems.

This webinar, presented by Joanne Stekler, MD, MPH, and Vanessa McMahan, MS, PhDc, defined pre-exposure prophylaxis (PrEP) for HIV and summarized the evidence of PrEP’s safety and efficacy for preventing HIV infection, focusing on populations who use substances. It also described research aimed at increasing access and adherence to PrEP among individuals who use methamphetamine in Seattle, Washington. Download slides | Watch recording

This presentation by Professor Katherine Sorsdahl discusses the Screening, Brief Intervention, and Referral to Treatment (SBIRT) training model with applications in the South African context. Katherine Sorsdahl is a Professor and the Co-Director of the Alan J Flisher Centre for Public Mental Health at the University of Cape Town. She also serves as Expert Curriculum Development Advisor for the South Africa HIV ATTC.

This presentation by Professor Bronwyn Myers discusses the Screening, Brief Intervention, and Referral to Treatment (SBIRT) training model in application to substance use disorders. Professor Bronwyn Myers is a Chief specialist scientist in the Alcohol Tobacco and Other Drug Use Research Unit at the South African Medical Research Council. Professor Myers also serves as an Expert Technical Assistance Advisor for the South Africa HIV ATTC.

Monthly electronic newsletter

The double-sided sheet provides information on what recovery means, what you can do to help persons with substance use disorders, and information about the current opioid crisis. Although the document was initially designed for the faith community, it is appropriate as an educational flyer for much broader audiences, including community health centers, treatment agencies, social service agencies, and other groups.

A presentation on Behavioral Therapies for Methamphetamine Use, presented by Will M. Aklin, PhD of the National Institute on Drug Abuse Division of Therapeutics and Medical Consequences on June 27, 2017.

Crystal methamphetamine use has increased among MSM of Color in New York City in the past few years. This webinar will introduce participants to crystal methamphetamine use among MSM. This webinar will introduce participants to crystal methamphetamine use among MSM. It will describe crystal meth, reasons why MSM of Color are using it, the effect of crystal meth on HIV, routes of administration, pharmacology, and treatment options.

Monthly electronic newsletter highlighting Great Lakes ATTC training events and other topics.

Monthly electronic newsletter featuring Great Lakes ATTC training events and other topics.

The purpose of this introductory training is to provide HIV clinicians (including, but not limited to physicians, dentists, nurses, and other allied medical staff, therapists and social workers, and counselors, specialists, and case managers) with a detailed overview of cocaine, methamphetamine, and HIV.

Self-paced online course that contains six modules of instruction covering topics related to Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. Topics include: understanding the scope of alcohol and drug abuse/dependence; research why dentists need to understand SUDs; and an overview on how to implement the SBIRT model in dental settings.

The Journal of the Arizona Dental Association-Inscriptions, Volume 25, Number 13, September 2011 featured an article focused on the potential of patient abuse of prescription drugs, especially opioid based medication prescribed by dental practitioners to manage pain. Provided in the article are data and ways to engage patients in conversation regarding their prescription drug use.